KR20230149976A - Composition for prevention and treatment of inflammation containing 8-epiasterolid extracted from atractylodes macrocephala as active ingredient - Google Patents

Abstract

The present invention relates to a composition for preventing and treating inflammatory reactions, and more specifically, to a composition for preventing and treating inflammatory reactions containing 8-epiasterolide extracted from Baekchul as an active ingredient. As 8-epiasterolide, the active ingredient of the present invention, is effective in alleviating, improving and treating inflammatory reactions, the present invention reduces the risk of developing inflammatory diseases due to excessive inflammatory reactions and prevents various inflammatory reactions. , It can be used as medicine, food, and quasi-drugs for improvement and treatment.

Description

A composition for preventing and treating inflammatory reactions containing 8-epiasterolide extracted from Baekchul as an active ingredient {COMPOSITION FOR PREVENTION AND TREATMENT OF INFLAMMATION CONTAINING 8-EPIASTEROLID EXTRACTED FROM ATRACTYLODES MACROCEPHALA AS ACTIVE INGREDIENT}

The present invention relates to a composition for preventing and treating inflammatory reactions, and more specifically, to a composition for preventing and treating inflammatory reactions containing 8-epiasterolide extracted from Baekchul as an active ingredient.

Inflammation can be said to be a series of biological reactions that seek to minimize local damage and restore the original state. This inflammatory reaction mainly occurs around blood vessels and blood cells. Inflammatory reactions can be largely divided into acute and chronic. The acute case is immediate and non-specific and is characterized by infiltration of polymorphonuclear leukocytes. Systemic symptoms include fever, fatigue, loss of appetite, and weakness, and local symptoms include redness and localized symptoms. Examples include fever, swelling, pus, and pain. In chronic inflammation, monocytes (macrophages, lymphocytes, and plasma cells) gather, fibroblasts and capillaries proliferate, and collagen fibers produced by fibroblasts are deposited, leading to fibrosis. At this time, tissue destruction appears more severe than in acute inflammation. The morphological classification of inflammation varies depending on the type and size of the stimulus, the degree of inflammatory reaction, and the type of damaged tissue, and mainly appears as serous inflammation, fibrinous inflammation, purulent inflammation, and ulcers. Recently, various inflammatory diseases such as acute inflammation and chronic inflammation such as rheumatoid arthritis are on the rise among modern people. To treat inflammation, drugs such as antibiotics and anti-inflammatory drugs are used, but side effects are increasingly becoming a problem.

The characteristics of the inflammatory response are a large distribution of inflammatory blood cells (leukocytes, neutrophils, macrophages, etc.), their progenitor cells, and HSCs in the blood, an increase in inflammatory cytokines (TNF-alpha, IL2, IL4, IL6, etc.), and an increase in anti-inflammatory cytokines. It is characterized by a decrease in inflammatory cytokines (IL10, etc.) (Eva Mezey et al, Nature Medicine 2009 vol15, 42-49). Additionally, many inflammatory cells accumulate in the damaged tissue.

In general, the inflammatory response is one of the biological defense responses of the innate immune response, but reactive oxygen species and proteolytic enzymes secreted by inflammatory cells, especially neutrophil cells, cause serious damage to surrounding tissues. Therefore, if the inflammatory reaction is prolonged, it develops into a chronic or intractable ulcer, and even after healing, it changes into fibrosis, causing sclerosis of the tissue and significantly reducing the function of the tissue.

Although research is being actively conducted on diseases related to inflammatory reactions and their mechanisms, limitations of existing drug treatments are being pointed out. Therefore, there is a need for natural products or drugs derived from natural products that effectively treat and improve inflammatory responses but do not cause organ damage or toxicity.

Meanwhile, Baekchul is a perennial herb belonging to the Asteraceae family. It is made by trimming and drying the root of the spatula, and is also called Sangae or Cheongae. Baekchul is very bitter and has a slightly sweet taste. The ones with white insides and cold eggs are good, and those collected in the fall are known to be especially effective.

It is good for people who have weak nasogastric function, feel tired, have a yellow complexion, have watery stools, or have diarrhea. It helps excrete moisture when the entire body swells and digestion is difficult due to stagnant moisture. It is also used for heartbeat, coughing, and clear phlegm caused by water and moisture accumulating in the spleen, and for vomiting during pregnancy and when sweating occurs naturally on the skin due to weakness in the spleen. Also used. It is also used for colds with gastrointestinal disorders and pain in the extremities. Pharmacologically, it has been reported to increase body weight and endurance in mice, increase phagocytosis ability, and promote cellular immune function. In addition, it has been reported to regulate intestinal suppression and excitability, anti-ulcer and liver function protection, immune function enhancement, vasodilation, diuretic and blood sugar lowering effects, and anticancer activity.

Accordingly, the present inventors extracted a large amount of water-soluble active ingredients by thermally extracting the white extract with distilled water, and completed the present invention by confirming that the extract of the white extract can improve, alleviate, and treat inflammatory reactions.

Republic of Korea Patent Publication No. 10-0543075 (2006.01.06)

Eva Mezey et al, Nature Medicine 2009 vol15, 42-49

The purpose of the present invention is to provide a composition for preventing and treating inflammatory reactions containing 8-epiasterolide extracted from Baekchul as an active ingredient.

In order to achieve the above object, the present invention discloses a pharmaceutical composition for preventing and treating inflammatory reactions, which contains an extract of Chrysanthemum chinensis as an active ingredient.

Here, the Baekchul extract may be 8-epiasterolid represented by the following formula (1).

[Formula 1]

Here, the white extract may be an extract obtained by extracting white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

Here, the pharmaceutical composition is used in the form of an oral dosage form selected from the group consisting of powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterilized aqueous solutions. It may be.

Meanwhile, in order to achieve the above object, the present invention further discloses a food composition for preventing and alleviating inflammatory reactions, comprising an extract of Chrysanthemum chinensis.

Here, the Baekchul extract may be 8-epiasterolid represented by the following formula (1).

[Formula 1]

Here, the white extract may be an extract obtained by extracting white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

Meanwhile, in order to achieve the above object, the present invention further discloses a quasi-drug composition for preventing and improving inflammatory reactions, comprising an extract of Chrysanthemum Chrysanthemum.

Here, the Baekchul extract may be 8-epiasterolid represented by the following formula (1).

[Formula 1]

Meanwhile, in order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating inflammatory reactions, comprising the step of preparing a white extract by extracting the white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The manufacturing method is further disclosed.

As 8-epiasterolide, the active ingredient of the present invention, is effective in alleviating, improving and treating inflammatory reactions, the present invention reduces the risk of developing inflammatory diseases due to excessive inflammatory reactions and prevents various inflammatory reactions. , It can be used as medicine, food, and quasi-drugs for improvement and treatment.

Figure 1 graphically shows the cytotoxicity evaluation of the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.
Figure 2 graphically shows the evaluation of prostaglandin production in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.
Figure 3 graphically shows the evaluation of the production of inflammatory cytokines in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.
Figure 4 graphically shows the evaluation of inflammatory factor enzyme expression in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.
Figure 5 is a graph showing the evaluation of nuclear factor kappa B pathway activity in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.

The terms used in this application are only used to describe specific examples. Therefore, for example, a singular expression includes a plural expression, unless the context clearly requires it to be singular. In addition, terms such as “comprise” or “comprise” used in the present application are used to clearly indicate the presence of features, steps, functions, components, or combinations thereof described in the specification, and are used to clearly indicate the presence of other features. It should be noted that it is not used to preliminarily rule out the existence of any elements, steps, functions, components, or combinations thereof.

Meanwhile, unless otherwise defined, all terms used in this specification should be viewed as having the same meaning as generally understood by those skilled in the art to which the present invention pertains. Therefore, unless clearly defined in this specification, specific terms should not be interpreted in an overly idealistic or formal sense.

The term "inflammatory response" used in the present invention refers to a complex biological reaction in response to body tissue damage caused by pathogens, damaged cells, or irritants, and includes physical/chemical factors such as chemicals, burns, frostbite, trauma, and pathogens. It includes all those caused by biological factors such as infection, immune response due to hypersensitivity, and stress. In addition, it is assumed to include both acute and chronic inflammatory responses.

The term “prevention” used in the present invention refers to all actions that suppress or delay the inflammatory response by administering the pharmaceutical composition or food composition according to the present invention.

The term “treatment” used in the present invention refers to any action in which symptoms related to an inflammatory response are improved or beneficially changed by administration of the pharmaceutical composition according to the present invention.

As used herein, the term "improvement" means any action that results in at least a reduction in the severity of a parameter, such as a symptom, associated with the condition being treated. The food composition according to the present invention can be used simultaneously or separately with a drug for treatment before or after the onset of the disease in order to prevent or improve inflammatory reactions.

The present invention discloses a pharmaceutical composition for preventing and treating inflammatory reactions, which contains an extract of Chrysanthemum chinensis as an active ingredient.

The Baekchul extract of the present invention may be 8-epiasterolid represented by the following formula (1).

The white extract can be used without restrictions, such as cultivated or commercially available. The white extract can be obtained by a conventional extraction method, and can be purchased and used commercially. The extract shall include any of the following: an extract obtained by extraction treatment, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, or a crude or purified product thereof.

The method for preparing the extract is not particularly limited, and it can be extracted according to a method commonly used in the art. Non-limiting examples of methods for producing the extract include hot water extraction, ultrasonic extraction, filtration, reflux extraction, immersion extraction, high temperature and high pressure steam extraction, etc., which can be performed alone or by combining two or more methods. It can be done.

Additionally, the white extract of the present invention may be extracted using a hydrophilic solvent. The hydrophilic solvent may be water, C1 to C10 alcohol, or a mixture thereof. The alcohol may be a compound having one or more -OH groups of C1 to C10, C1 to C6, or C1 to C4. The alcohol may be methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, tert-butanol, or mixtures thereof. Furthermore, the white extract is preferably an extract extracted with water, a lower alcohol having 1 to 4 carbon atoms, or a mixture thereof, but is not limited thereto.

Furthermore, it is more preferable that the white extract of the present invention is an extract obtained by hot water extraction at a temperature range of 80 to 120° C. for about 1 to 3 hours.

In addition, the white extract of the present invention includes a fraction obtained by fractionating the extract again, and the fraction is prepared by using one or more solvents selected from the group consisting of chloroform, ethyl acetate, butanol, methanol and water. It may be a fraction.

In addition to the above active ingredients, the pharmaceutical composition of the present invention may further include appropriate carriers, excipients, and diluents commonly used in the preparation of pharmaceutical compositions. The pharmaceutical composition of the present invention may further include other pharmaceutically active ingredients or active mixtures.

The pharmaceutical composition of the present invention can be prepared in oral dosage forms such as patches, coatings, powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions according to conventional methods. It can be formulated and used in a form. More specifically, the pharmaceutical composition is formulated in the form of an oral dosage form selected from the group consisting of powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, external preparations, suppositories, and sterilized aqueous solutions. can be used

Carriers, excipients and diluents that may be included in the composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Examples include methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc. These solid preparations contain at least one excipient, such as starch, calcium carbonate, sucrose ( It is prepared by mixing sucrose, lactose, and gelatin. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, oral solutions, emulsions, syrups, etc. In addition to the commonly used simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. Non-aqueous solvents and suspensions include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, Witepsol, Macrogol, Tween 61, cacao, laurin, glycerogenatin, etc. can be used.

The preferred dosage of the pharmaceutical composition of the present invention varies depending on the patient's condition and weight, degree of disease, drug form, administration route and period, but can be appropriately selected by a person skilled in the art. Administration may be administered once a day, or may be administered several times. The above dosage does not limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans through various routes. All modes of administration are contemplated, for example, oral, transdermal, rectal or intravenous, intramuscular, subcutaneous, by injection.

Definitions of the excipients, binders, disintegrants, lubricants, flavoring agents, etc. of the present invention are those described in literature known in the art and include those with the same or similar functions.

Meanwhile, the present invention further discloses a food composition for preventing and alleviating inflammatory reactions, comprising an extract of Chrysanthemum Chrysanthemum. Furthermore, the present invention further discloses a quasi-drug composition for preventing and improving inflammatory reactions, a health functional food, etc., containing an extract of White Chrysanthemum.

The Baekchul extract of the present invention may be 8-epiasterolid represented by the following formula (1).

[Formula 1]

The white extract of the present invention may be an extract obtained by extracting white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.

The Baekchul extract of the present invention may be included in a weight ratio of 0.01 to 99.99% based on the total food composition.

The Baekchul extract of the present invention may be included in a weight ratio of 0.01 to 99.99% based on the total quasi-drug composition.

The health functional food or food composition may contain Baekchul extract alone or together with other foods or food ingredients, and may be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use (prevention, health, or therapeutic treatment). Generally, when producing a food or beverage, the composition of the present invention is used in an amount of 15 parts by weight or less, 10 parts by weight or less, 1 to 15 parts by weight, 1 to 10 parts by weight, 1 to 5 parts by weight, based on the total weight. Alternatively, it may be added in an amount of 0.1 to 15 parts by weight. However, in the case of long-term intake for the purpose of health and hygiene or health control, the amount may be below the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount above the above range.

There are no special restrictions on the types of foods above. Examples of foods to which the above substances can be added include meat, sausages, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, These include alcoholic beverages and vitamin complexes, and include all foods in the conventional sense. The food composition can be used, for example, as food ingredients such as milk and yogurt, food and beverages, and functional foods. The food composition may contain various flavoring agents or natural carbohydrates as additional ingredients. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame can be used.

The food composition of the present invention also contains nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonated drinks. It may contain a carbonating agent used for, or a combination thereof. The food composition of the present invention may also contain pulp for the production of natural fruit juice, fruit juice beverage, vegetable beverage, or a combination thereof. These additives may be selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition.

The quasi-drug composition of the present invention refers to a product that exhibits the effect of treating, alleviating, treating, or preventing a disease, but has a milder effect on the human body than a pharmaceutical. Excludes products used for pharmaceutical purposes under the Pharmaceutical Affairs Act, and includes products according to classification standards separately set by the Ministry of Health and Welfare. Specifically, it may be an external skin preparation or a personal hygiene product, but is not limited thereto.

When adding the composition of the present invention to a quasi-drug composition, the composition can be added as is or used together with other quasi-drug ingredients, and can be used appropriately according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use.

Meanwhile, the present invention further provides a method for producing a pharmaceutical composition for preventing and treating inflammatory reactions, comprising the step of preparing a white extract by extracting the white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. Begin.

The Baekchul extract of the present invention may be 8-epiasterolid represented by the following formula (1).

[Formula 1]

The composition may be a pharmaceutical, health functional food, food, or quasi-drug composition.

Redundant content is omitted in consideration of the complexity of the present specification, and terms not otherwise defined in this specification have meanings commonly used in the technical field to which the present invention pertains.

Hereinafter, what the present specification claims will be described in more detail with reference to the accompanying drawings and examples. However, the drawings, examples, etc. presented in this specification can be modified in various ways by those skilled in the art to have various forms, and the description in this specification does not limit the present invention to a specific disclosed form. It should be viewed as including all equivalents or substitutes included in the spirit and technical scope of the present invention. In addition, the attached drawings are presented to help those skilled in the art understand the present invention more accurately, and may be shown exaggerated or reduced compared to reality.

{Examples and Evaluation}

1. Research background

Using a pharmaceutical composition for preventing and treating inflammatory reactions containing 8-epiasterolid extracted from Baekchul as an active ingredient, prevention, treatment, improvement, relief, etc. of inflammatory reactions in animal models with inflammation. It was confirmed whether it was effective. We aimed to confirm the excellent anti-inflammatory effect on mouse-derived macrophages and microglial cells, and since lipopolysaccharide (LPS) is known to be a substance that causes inflammatory reactions, lipopolysaccharide (LPS) was treated to induce inflammation. was formed.

2. Experimental example (cell model experiment inducing inflammatory response)

2.1. Experimental design

In this experiment, a cell model inducing an inflammatory response was created by treating the RAW264.7 cell line, a mouse-derived macrophage cell line, and the BV2 cell line, a mouse-derived microglial cell line, with lipopolysaccharide (LPS). The experimental group was divided as follows.

① Comparative example 1. control group

② Comparative example 2. LPS group (1 ㎍/mL)

③ Example 1. LPS + 8-epiasterolid group (20 μM)

④ Example 2. LPS + 8-epiasterolid group (40 μM)

⑤ Example 3. LPS + 8-epiasterolid group (80 μM)

2.3. Experiment method

Cytotoxicity evaluation, prostaglandin production evaluation, inflammatory cytokine production evaluation, inflammatory factor enzyme expression evaluation, nuclear factor kappa for normal group, comparison group (inflammatory group), and experimental group (8-epiasterolide treated group). B pathway activity evaluation, etc. were performed.

3. Evaluation

3.1. Evaluation of cytotoxicity by administration of 8-epiasterolide

Figure 1 graphically shows the cytotoxicity evaluation of the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.

Referring to Figure 1, 8-epiasterolide derived from Baekchul did not show cytotoxicity up to a concentration of 80 μM (Examples 1 to 3), and compared to the normal group (Comparative Example 1), lipopolysaccharide treatment It can be seen that the production of nitric oxide increased in the inflammation-inducing group (Comparative Example 2), and the production of nitric oxide was suppressed in the 8-epiasterolide-treated group. The 8-epiasterolide-treated group (Examples 1 to 3) showed a significant difference compared to the inflammation-induced group (Comparative Example 2) due to lipopolysaccharide treatment when tested at 95% (***p < 0.001).

3.2. Evaluation of prostaglandin production by administration of 8-epiasterolide

Figure 2 graphically shows the evaluation of prostaglandin production in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.

Referring to Figure 2, compared to the normal group (Comparative Example 1), the production of prostaglandins increased in the inflammation-induced group (Comparative Example 2) following lipopolysaccharide treatment, and the 8-epiasterolide treated group (Example In 2 and 3), it can be seen that the production of prostaglandin is suppressed. There was a significant difference when tested at 95% in the 8-epiasterolide-treated group (Example 3) compared to the inflammation-induced group due to lipopolysaccharide treatment (Comparative Example 2) (**p < 0.01, * **p < 0.001).

3.3. Evaluation of inflammatory cytokine production by administration of 8-epiasterolide

Figure 3 graphically shows the evaluation of the production of inflammatory cytokines in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.

Referring to Figure 3, compared to the normal group (Comparative Example 1), the production of inflammatory cytokines increased in the inflammation-induced group (Comparative Example 2) following lipopolysaccharide treatment, and the 8-epiasterolide treated group (Example In Examples 2 and 3), it can be confirmed that the production of inflammatory cytokines is suppressed. There was a significant difference when tested at 95% in the 8-epiasterolide-treated group (Example 3) compared to the inflammation-induced group due to lipopolysaccharide treatment (Comparative Example 2) (**p < 0.01, * **p < 0.001).

3.4. Evaluation of inflammatory factor enzyme expression by administration of 8-epiasterolide

Figure 4 graphically shows the evaluation of inflammatory factor enzyme expression in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.

Referring to Figure 4, compared to the normal group (Comparative Example 1), the expression of inflammatory factor enzymes increased in the inflammation-induced group (Comparative Example 2) following lipopolysaccharide treatment, and the 8-epiasterolide treated group ( In Examples 2 and 3), it can be confirmed that the expression of iNOS and COX-2 proteins, which are inflammatory factor enzymes, is suppressed.

3.5. Evaluation of nuclear factor kappa B pathway activity by administration of 8-epiasterolide

Figure 5 is a graph showing the evaluation of nuclear factor kappa B pathway activity in the normal group, the inflammation-induced group following lipopolysaccharide treatment, and the 8-epiasterolide treatment group.

Referring to Figure 5, compared to the normal group (Comparative Example 1), the nuclear factor kappa B pathway was activated in the inflammation-induced group (Comparative Example 2) following lipopolysaccharide treatment, and the 8-epiasterolide treated group ( In Examples 2 and 3), it can be confirmed that the activity of the pathway is suppressed. In the 8-epiasterolide treated group (Examples 2 and 3), the phosphorylation and extinction reactions of IκB-α and the phosphorylation reactions of p65 were inhibited.

From the above-mentioned experimental examples, the production and expression of inflammatory factors and the efficacy of suppressing the activation of inflammatory response mechanisms were verified in macrophage and microglial cell models in which inflammatory responses were induced with lipopolysaccharide (LPS).

Considering the details of the examples and evaluations, 8-epiasterolide, the active ingredient of the present invention, is effective in alleviating, improving, and treating inflammatory reactions, and thus, the present invention is effective in treating inflammatory diseases caused by excessive inflammatory reactions. It can be confirmed that it reduces the risk of developing , and can be used as medicine, food, and quasi-drugs for the prevention, improvement, and treatment of various inflammatory reactions.

The above description is merely an illustrative explanation of the technical idea of the present invention, and various modifications and variations will be possible to those skilled in the art without departing from the essential characteristics of the present invention.

Accordingly, the embodiments disclosed in the present invention are not intended to limit the technical idea of the present invention, but are for illustrative purposes, and the scope of the technical idea of the present invention is not limited by these embodiments. The scope of protection of the present invention should be interpreted in accordance with the claims below, and all technical ideas within the equivalent scope should be construed as being included in the scope of rights of the present invention.

Claims (10)

A pharmaceutical composition for preventing and treating inflammatory reactions, containing extract of Chrysanthemum Chrysanthemum as an active ingredient.
According to paragraph 1,
A pharmaceutical composition for preventing and treating inflammatory reactions, wherein the Baekchul extract is 8-epiasterolid represented by the following formula (1).
[Formula 1]

According to paragraph 1,
The pharmaceutical composition for preventing and treating inflammatory reactions, wherein the white extract is an extract obtained by extracting white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
According to paragraph 1,
The pharmaceutical composition is characterized in that it is formulated and used in the form of an oral dosage form selected from the group consisting of powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized aqueous solutions. A pharmaceutical composition for preventing and treating inflammatory reactions.
A food composition for preventing and improving inflammatory reactions, comprising an extract of Chrysanthemum chinensis.
According to clause 5,
A food composition for preventing and improving inflammatory reactions, wherein the Baekchul extract is 8-epiasterolid represented by the following formula (1).
[Formula 1]

According to clause 5,
The food composition for preventing and improving inflammatory reactions, wherein the white extract is an extract obtained by extracting white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
A quasi-drug composition for preventing and improving inflammatory reactions, comprising an extract of Chrysanthemum Chrysanthemum.
According to clause 8,
A quasi-drug composition for preventing and improving inflammatory reactions, wherein the Baekchul extract is 8-epiasterolid represented by the following formula (1).
[Formula 1]

A method for producing a pharmaceutical composition for preventing and treating inflammatory reactions, comprising: preparing a white extract by extracting the white extract with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.